Item 8.01 Other Events.

On June 2, 2020, Menlo Therapeutics Inc. (the "Company") issued a press release announcing positive results from a Phase 2 clinical trial evaluating the preliminary safety and efficacy of FCD105 (3% minocycline / 0.3% adapalene foam), the first ever topical minocycline-based combination product, for the treatment of moderate-to-severe acne vulgaris. A copy of the press release is attached as Exhibit 99.1 to this report.

In addition, members of senior management of the Company will be using the Investor Presentation attached as Exhibit 99.2 (the "Presentation") to this report in connection with providing a corporate overview at the Jefferies Virtual Healthcare Conference on June 2, 2020. The Presentation is incorporated into this Item 8.01 by reference.

Item 9.01. Financial Statements and Exhibits.





(d) Exhibits

The following exhibits are filed herewith.





Exhibit No.   Description
  99.1          Press release, entitled "Menlo Therapeutics Announces Positive
              Results from Phase 2 Trial of FCD105 for the Treatment of
              Moderate-to-Severe Acne Vulgaris."

  99.2          Investor Presentation.

© Edgar Online, source Glimpses